Company news
Hbm Holdings Ltd. (HKEX:2142) news
Hbm Holdings Ltd. news releases on 6ix. Latest, May 8, 2026: Harbour BioMed Announces U.S. FDA IND Clearance for HBM7004 for the Treatment of Advanced Solid…
Press releases & updates
Harbour BioMed Announces U.S. FDA IND Clearance for HBM7004 for the Treatment of Advanced Solid Tumors
May 8, 2026
Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis
March 9, 2026
Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results
February 2, 2026
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
January 17, 2026
Control Devices Acquires Sherwood Valve
January 12, 2026
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
December 27, 2025
Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies
December 15, 2025
Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
November 22, 2025
Harbour BioMed and Evinova China Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development
November 7, 2025
Harbour BioMed Launches First Fully Human Generative AI HCAb Model to Accelerate Next-Generation Biologics Discovery
October 28, 2025
Harbour BioMed Announces Positive Phase II Results for HBM4003 and Tislelizumab Combination in MSS mCRC
October 21, 2025
Harbour BioMed Reports 2025 Interim Results
August 27, 2025
Harbour BioMed Appoints Yajie Li as Chief Medical Officer
August 23, 2025
Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025
July 28, 2025
Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results
July 26, 2025
HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma
July 23, 2025
Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers
June 21, 2025
China National Intellectual Property Administration Affirms Validity of Harbour BioMed's Patent; Infringement Lawsuit Moves Forward
June 16, 2025
Harbour BioMed Appoints Youchen Chen as Chief Financial Officer
April 8, 2025
Harbour BioMed Reports Full Year 2024 Financial Results
March 31, 2025
Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies
March 21, 2025
Harbour BioMed Launches Élancé Therapeutics to Advance Next-Generation Obesity Therapies
March 12, 2025
Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer
March 9, 2025
Harbour BioMed Appoints Dr. Ian Y. Liu as Global Head of Legal
March 9, 2025
Harbour BioMed and Insilico Medicine Achieve Strategic Collaboration to Advance AI-Driven Antibody Discovery and Development
February 20, 2025
Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results
July 18, 2024
Harbour BioMed Reports Full Year 2023 Financial Results
March 28, 2024
Harbour BioMed Announces Positive Profit Alert
January 17, 2024
Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director
August 8, 2023
Harbour BioMed Announces 2023 Interim Results Positive Profit Alert with the Enhancement of Value Driven by Innovation
July 13, 2023
Harbour BioMed Reports Full Year 2022 Financial Results
April 3, 2023
HBM Alpha Therapeutics Raises Seed Round to Advance Next-Gen Therapies for Endocrine Disorders
January 25, 2023
Harbour BioMed Enters into a License and Collaboration Agreement with Moderna
November 9, 2022
Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board
May 4, 2022
Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022
April 5, 2022
Harbour BioMed Reports Full Year 2021 Financial Results: Empower Value Creation with Global Innovation Capabilities
March 23, 2022
Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003
January 4, 2022
Harbour BioMed : Announces NMPA Approval of Two IND Applications for Next-Generation Anti-CTLA-4 Antibody HBM4003
September 14, 2021
HBM : VOLUNTARY ANNOUNCEMENT - DOSING OF FIRST PATIENT IN PHASE Ib/IIa CLINICAL STUDY OF NEXT-GENERATION ANTI-CTLA-4 ANTIBODY IN AUSTRALIA
May 12, 2021